Author

Hesuiyuan Wang

The University of Texas Southwestern Medical Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Andrew Young KohiD· 2 shared Christina M. ZarekiD· 2 shared Jake N. LichtermaniD· 2 shared Jiwoong KimiD· 2 shared Nicole A. PoulidesiD· 2 shared Parastoo SabaeifardiD· 2 shared Tarun SrinivasaniD· 2 shared Wenling LiiD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrew Young KohORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A microbiota-derived bile acid overcomes antibiotic-induced hyporesponsiveness to immune checkpoint therapy by enhancing CD8+ T cell antitumor immunity

Wenling Li, Christina M. Zarek, Hesuiyuan Wang, Shuheng Gan, Parastoo Sabaeifard, Priscilla Del Valle, Jiwoong Kim, Nicole A. Poulides, Laura Coughlin, Jake N. Lichterman, Cheng Cheng Zhang, Rebecca Suet-Yan Chiu, Tarun Srinivasan, Mauricio J. Velasquez, Indu Raman, , Andrew Young Koh

This study identifies TDCA, a microbiota-derived bile acid, as a mediator that restores immune checkpoint therapy efficacy after antibiotic-induced hyporesponsiveness by enhancing CD8+ T cell antitumor immunity.

bioRxiv · Apr 19, 2026 · PreprintCancer Biology

Timing of immune checkpoint blockade shapes anti-tumor immunity via a clock-dependent chemokine axis

Jake N. Lichterman, Tarun Srinivasan, Ruheng Wang, Chaitanya Dende, Christina M. Zarek, Josue I. Ramirez, Noheon Park, Hesuiyuan Wang, Wenling Li, Jiwoong Kim, Laura A. Coughlin, Nicole A. Poulides, Parastoo Sabaeifard, Suzette N. Palmer, Aidan C. Morrill, , Andrew Young Koh

This study shows that the time of day affects cancer immunotherapy efficacy through a circadian clock-dependent chemokine axis in mice.

bioRxiv · Nov 3, 2025 · PreprintImmunology